Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative AnalysisCarolina Terragna, Michèle Cavo, Chiara Nozzoli et al.|Blood|2010Cited by 13
Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.Michèle Cavo, Michele Baccarani, Nicoletta Testoni et al.|Blood|2008Cited by 10
Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 PatientsElena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Blood|2010Cited by 7
Prognostic impact of cytogenetic abnormalities in newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous stem-cell transplantation: A prospective analysis of 593 patientsElena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|F1000Research|2010Cited by 0
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLSCarolina Terragna, Michèle Cavo, Daniel Remondini et al.|Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)|2010Cited by 0